Grifols Purchases Talecris Biotherapeutics, Manufacturer of Prolastin-C Augmentation Therapy for A1
The U.S. Federal Trade Commission today approved the Grifols purchase of Talecris Biotherapeutics, the manufacturer of Prolastin-C augmentation therapy for Alpha-1 Antitrypsin Deficiency.
Talecris is the manufacturer of Prolastin-C, the dominant augmentation therapy for Alpha-1 Antitrypsin Deficiency in the United States.
The Spanish company, as a concession to Italian competitor Kedrion, agreed to divest in a plant in New York, two centers in Alabama and North Carolina and the exclusive rights to sell the hemophilia therapy Factor VIII under the Koate brand as part of the deal.
Grifols launched an offer for Talecris last June in a move to expand its business in blood-derived products and compete with larger rivals Baxter and Australia’s CSL.
Click here to read more.